Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.

Abramson JS, Hochberg EP.

Cancer. 2010 Dec 14. [Epub ahead of print] No abstract available.

PMID:
21157960
[PubMed - as supplied by publisher]
Free Article
2.

Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type.

Perez-Soler R, Smith TL, Cabanillas F.

Cancer. 1986 Mar 1;57(5):971-7.

PMID:
3753657
[PubMed - indexed for MEDLINE]
3.

Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.

van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E.

Leuk Lymphoma. 2008;49 Suppl 1:52-8. doi: 10.1080/10428190802311458. Review.

PMID:
18821433
[PubMed - indexed for MEDLINE]
4.

CNS prophylaxis in lymphoma: who to target and what therapy to use.

Hill QA, Owen RG.

Blood Rev. 2006 Nov;20(6):319-32. Epub 2006 Aug 1. Review.

PMID:
16884838
[PubMed - indexed for MEDLINE]
5.

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.

O'Rourke K, Morris K, Kennedy GA.

Cancer. 2011 Jun 1;117(11):2579-80; author reply 2580-1. doi: 10.1002/cncr.25784. Epub 2010 Dec 14. No abstract available.

PMID:
24048807
[PubMed - indexed for MEDLINE]
Free Article
6.

Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.

Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Brière J, Reyes F.

Ann Oncol. 2000 Jun;11(6):685-90.

PMID:
10942056
[PubMed - indexed for MEDLINE]
Free Article
7.

Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.

Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E; Programa para el Estudio y Tratamiento de Hemopatias Malignas Group.

Cancer. 2006 Jun 15;106(12):2540-6.

PMID:
16700036
[PubMed - indexed for MEDLINE]
Free Article
8.

The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.

Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A.

Ann Oncol. 2007 Mar;18(3):541-5. Epub 2006 Dec 12.

PMID:
17164228
[PubMed - indexed for MEDLINE]
Free Article
9.

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B.

Ann Oncol. 2004 Jan;15(1):129-33.

PMID:
14679132
[PubMed - indexed for MEDLINE]
Free Article
10.

Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.

Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y.

Cancer. 2002 Aug 1;95(3):576-80.

PMID:
12209750
[PubMed - indexed for MEDLINE]
Free Article
11.

Central nervous system involvement in diffuse large B-cell lymphoma.

Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y.

Eur J Haematol. 2010 Jul;85(1):6-10. doi: 10.1111/j.1600-0609.2010.01438.x. Epub 2010 Mar 3.

PMID:
20236301
[PubMed - indexed for MEDLINE]
12.

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.

Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM.

Blood. 1995 Sep 15;86(6):2091-7.

PMID:
7662956
[PubMed - indexed for MEDLINE]
Free Article
13.

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2007 Jan;18(1):149-57. Epub 2006 Oct 3.

PMID:
17018708
[PubMed - indexed for MEDLINE]
Free Article
14.

Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.

Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T; IVL Study Group in Japan.

Cancer Sci. 2010 Jun;101(6):1480-6. doi: 10.1111/j.1349-7006.2010.01555.x. Epub 2010 Mar 6.

PMID:
20412122
[PubMed - indexed for MEDLINE]
15.

Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience.

Shimazu Y, Notohara K, Ueda Y.

Int J Hematol. 2009 Jun;89(5):577-83. doi: 10.1007/s12185-009-0289-2. Epub 2009 Apr 9.

PMID:
19353238
[PubMed - indexed for MEDLINE]
16.

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F.

Blood. 1998 Feb 15;91(4):1178-84.

PMID:
9454747
[PubMed - indexed for MEDLINE]
Free Article
17.

Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.

Mahoney DH Jr, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, Lauer SJ, Steuber CP, Kamen BA.

Cancer. 1995 May 15;75(10):2623-31.

PMID:
7736409
[PubMed - indexed for MEDLINE]
18.

Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.

Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM.

Br J Haematol. 2005 Oct;131(2):193-200. Erratum in: Br J Haematol. 2005 Dec;131(5):673.

PMID:
16197449
[PubMed - indexed for MEDLINE]
19.

Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.

Moe PJ, Holen A, Nygaard R, Glomstein A, Madsen B, Hellebostad M, Stokland T, Wefring KW, Steen-Johnsen J, Nielsen B, Hapnes C, Børsting S.

Pediatr Hematol Oncol. 2003 Apr-May;20(3):187-200.

PMID:
12637215
[PubMed - indexed for MEDLINE]
20.

Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.

Lee KW, Yi J, Choi IS, Kim JH, Bang SM, Kim DW, Im SA, Kim TY, Yoon SS, Lee JS, Bang YJ, Park S, Kim BK, Cho HI, Heo DS.

Ann Hematol. 2009 Sep;88(9):829-38. doi: 10.1007/s00277-008-0682-6. Epub 2009 Jan 27.

PMID:
19172274
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk